A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy

Nature Biotechnology

Volumn 15, Issue 13, 1997, Pages 1373-1377

  Marais, Richard ^a   Spooned, Robert A ^a   Stribbling, Stephen M ^a   Light, Yvonne ^a   Martin, Janet ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bystander effect; Cancer therapy; Drug delivery; Enzyme engineering

Indexed keywords

CARBOXYPEPTIDASE G2; METHOTREXATE; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SENSITIVITY; ENZYME MODIFICATION; ENZYME SUBSTRATE; ENZYME THERAPY; GENE THERAPY; GLYCOSYLATION; HUMAN; HUMAN CELL; MAMMAL CELL; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; XENOGRAFT;

3T3 CELLS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; GAMMA-GLUTAMYL HYDROLASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTAMATES; GLYCOSYLATION; HUMANS; MEMBRANE PROTEINS; METHOTREXATE; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 0031437780     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt1297-1373     Document Type: Article

References (32)

1. Bridgewater, J., Springer, C.J., Knox, R., Minton, N., Michael, P., and Collins, M. 1995. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31 A:2362-2370.
2. Huber, B.E., Austin, E.A., Richards, C.A., Davis, S.T., and Good, S.S. 1994. Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91:8302-8306,
3. Zhang, W.W., Fujiwara, T., Grimm, E.A., and Roth, J.A. 1995. Advances in cancer gene therapy. Adv. Pharmacol. 12:289-341.
4. Niculescu-Duvaz, I. and Springer, C.J. 1997. Gene-directed enzyme prodrug therapy (GDEPT): a review of enzyme/prodrug combinations. Expert Opinion in Investigational Drugs 6:685-703.
5. Freeman, S.M., Abboud, C.N., Whartenby, K.A., Packman, C.H., Koeplin, D.S., Moolten, F.S., and Abraham, G.N. 1993. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:5274-5283.
6. Hughes, B.W., Wells, A.H., Bebok, Z., Gadi, V.K., Garver, R.I., Parker, W.B., and Sorsher, E.J. 1995. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55:3339-3345.
7. Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H., and Blaese, M.R. 1992. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550-1552.
8. Vile, R.G. and Hart, I.R. 1993. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53:3860-3864.
9. Nabel, G.J., Chang, A.E., and Nabel, E.G. 1994. Immunotherapy for cancer by direct gene transfer into tumors. Human Gene Ther. 5:57-77.
10. O'Malley, B.W. Jr., Chen, S.H., Schwartz, M.R., and Woo, S.L.C. 1995. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 55:1080-1085.
11. Tanaka, T., Kanai, F., Okabe, S., Yoshida, Y., Wakimoto, H., Hamada, H., et al. 1996. Adenovirus-mediated prodrug gene-therapy for carcinoembryonic antigen-producing human gastric-carcinoma cells in vitro. Cancer Res. 56:1341-1345.
12. Moolten, F.L. 1986. Tumor chemosensitivity conferred by inserted Herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46:5276-5281.
13. Borelli, E., Heyman, R., Hsi, M., and Evans, R.M. 1988. Targeting of an inducible toxic phenotype in animal cell. Proc. Natl. Acad. Sci. USA 85:7572-7576.
14. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J.L, and Klatzmann, D. 1993. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90:7024-7028.
15. Oldfield, E.H., Ram, Z., Culver, K.W., Blaese, R.M., and DeVroom, H.L 1993. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with thymidine kinase gene and intravenous ganciclovir. Human Gene Ther. 4:39-69.
16. Barba, D., Hardin, J., Ray, J., and Gage, F.H. 1993. Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79:729-735.
17. Black, M.E., Newcomb, T.G., Wilson, H.M., and Loeb, L.A. 1996. Creation of drug-specific herpes simplex virus type-1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA 93:3525-3529.
18. Sherwood, R.F., Melton, R.G., Alwan, S.M., and Hughes, P. 1985. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS16. Eur. J. Biochem. 148:447-453.
19. Springer, C.J., Antoniw, P., Bagshawe, K.D., Searle, F., Bisset, G.M.F., and Jarman, M. 1990. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33:677-681.
20. Marais, R., Spooner, R.A., Light, Y., Martin, J., and Springer, C.J. 1996. Gene-Directed Enzyme Prodrug Therapy (GDEPT) with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56:4735-4742.
21. Duksin, D. and Mahoney, W.C. 1982. Relationship of the structure and biological activity of the natural homolgues of tunicamycin. J. Biol. Chem. 257:3105-3109.
22. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, D., Warren, J.T., et al. 1990. New colorimetric cytotoxicity assay for anticancer screening. J. Natl. Cancer Inst. 82:1107-1112.
23. Raptis, I. and Firth, K.L. Electroporation of adherent cells in situ. 1990. DNA Cell Biol. 9:615-621.
24. Raptis, I., Firth, K.L, Brownell, H.L, Todd, A., Simon, W.C., Bennet, B.M., et al. (eds.). 1995. pp 93-113 in Electroporation of adherent cells in situ for the introduction of nonpermeant molecules. Humana Press, Inc., Totowa, NJ.
25. Chanson, M., Bruzzone, R., Bosco, D., and Meda, P. 1989. Effects of n-alcohols on junctional coupling and amylase secretion of pancreatic acinar cells. J. Cell. Physiol. 139:147-156.
26. Vile, R., Nelson, J.A., Castledon, S., Chang, H., and Hart, I. 1994. Systemic gene therapy of murine melanoma using tissue-specific expression of the HSV-TK gene involves an immune response. Cancer Res. 54:6228-6234.
27. Gagandeep, S., Brew, R., Green, B., Christmas, S.E., Klatzmann, D., Poston, G.J., and Kinsella, A.R. 1996. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect." Cancer Gene Ther. 3:83-88.
28. Pavlovic, J., Nawrath, M., Tu, R., Heinicke, T., and Moelling, K. 1996. Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-Ras (G12V). Gene Ther. 3:635-643.
29. Ramash, R., Marrogi, A.J., Munshi, A., Abboud, C.N., and Freeman, S.M. 1996. In vivo analysis of the 'bystander effect': a cytokine cascade. Exp. Hematol. 24:829-638.
30. Ramash, R., Munshi, A., Abboud, C.N., Marrogi, A.J., and Freeman, S.M. 1996. Expression of co-stimulatory molecule: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther. 3:373-384.
31. Springer, C.J. 1993. CMDA, an antineoplastic prodrug. Drugs of the Future 18:212-215.
32. Stribbling, S.M., Martin, J., Pedley, R.B., Boden, JA, Sharma, S.K., and Springer, C.J. 1997. Biodistribution of an antibody-enzyme conjugate for ADEPT in nude mice bearing a human colon adenocancinoma xenograft Cancer Chemother. Pharmacol. 40:277-284.